AAArman Ahmadzadeh

Arman Ahmadzadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arman Ahmadzadeh has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Compared Efficacy of Tocilizumab versus Rituximab in the Treatment of Refractory Rheumatoid Arthritis: A Randomized Clinical Trial study

    by Arman Ahmadzadeh, Faraneh Farsad, Alireza Rahaei, Mohammad Mehdi Emam, Latif Gachkar, Elnaz Shafighi Shahri

    Background & Objective: This study was carried out to compare the efficacy of tocilizumab versus rituximab in the treatment of refractory rheumatoid arthritis. Materials & Methods: Twenty-two women with refractory rheumatoid arthritis were randomly divided into rituximab (n= 11) and tocilizumab (n= 11) treatment groups. In the first group, rituximab ...


  • Open Access

    Evaluation of agreement coefficient between chest computed tomography and echocardiography in the diagnosis of pulmonary artery hypertension in patients with systemic sclerosis; a pilot study

    by Arman Ahmadzadeh, Mehdi Sheibani, Faraneh Farsad, Pooneh Dehghan, Latif Gachkar, Samad Nazarpoor

    Introduction: Systemic sclerosis (SSc) is an autoimmune disorder that often presents with skin involvement. SSc affects various organs, and one of the most important of these organs is the cardiovascular system, which is one of the complications of this syndrome, including pulmonary arterial hypertension (PAH). Early diagnosis of this complication is very important due to the importance of the effect of PAH on mortality and morbidity of patients. For diagnosis of PAH, two methods of computed tomography (CT) scan and echocardiography are conducted. Objectives: In this study, we aimed to evaluate the agreement coefficient of chest CT scan in comparison with echocardiography in the diagnosis of PAH in patients with SSc. Patients and Methods: In a diagnostic study, which was conducted in Loghman hospital (Tehran-Iran), patients with a diagnosis of SSc were evaluated for pulmonary artery pressure (PAP) by echocardiography. For patients, a CT scan of the lungs was conducted and PAP was assessed. The results that obtained from the lungs CT scan were compared with the echocardiography results. Results: Fifty patients with SSc were evaluated. Eighty-four percent of patients were female and the mean age of all patients was 48.94 ± 11.02 years. About 16% of all patients had high PAP based on echocardiography and 28% of patients based on CT scan. Kappa’s agreement coefficient was 0.428 and Spearman’s correlation coefficient was 0.457. In other words, chest CT scan has a partly agreement with the echocardiography method (P value = 0.001). Conclusion: Chest CT scan has a high sensitivity, specificity, and accuracy compared to echocardiography as a screening method.


  • Open Access

    The prevalence of self-quarantine for preventing COVID 19 involvement in patients with rheumatoid arthritis who used Disease-Modifying Anti-Rheumatic Drugs

    by Arman Ahmadzadeh, Sareh Basiri, Mohammadmahdi Emam, Alireza Rajaei, Faraneh Farsad

    Introduction: Rheumatoid Arthritis (RA) is an autoimmune disorder that is treated with classic Disease-Modifying Anti Rheumatic Drugs (DMARDs), which impair the immune system. It seems that self-quarantine is a good method for CVOID-19 prevention in patients with RA. Objectives: The aim of this study was to assessment the prevalence of self-quarantine for preventing COVID 19 involvement in patients with rheumatoid arthritis who used Disease-Modifying Anti-Rheumatic Drugs Methods and Materials: in this descriptive study that was performed in Loghman-Hakim Hospital (Tehran, Iran), patients with RA who took classic DMARDs and were referred to the hospital were assessed based on age, sex, medications, smoking, history of Covid-19 in a relatives, Covid-19 involvement in the patient, Covid-19 symptoms, and observing self-quarantine. Result: the mean age was 53.84 years old and 27.7% were male of one thousand patients with RA who took classic DMARDs. Covid-19 prevalence among these patients was 10.4%. The prevalence of COVID-19 was 21% among patients who didn’t observe self-quarantine and 9.2% among patients who observed self-quarantine. Self-quarantine lowered the risk of Covid-19 by around 60%. Conclusion: self-quarantine is a good method to reduce the prevalence of COVID-19 among RA patients who used classic DMARDs.

  • Diagnostic Value of Ultrasound for Detecting Carpal Tunnel Syndrome in Patients With Rheumatoid Arthritis: A Three-Arm Cross-Sectional Study

    by Masume Bayat, Zohreh Bagheri, Seyed Ahmad Raeissadat, Seyed Mansoor Rayegani, Arman Ahmadzadeh, Fatemeh Shirani

    Objective: This study was conducted to assess the diagnostic value of sonography in detecting carpal tunnel syndrome (CTS) in patients with rheumatoid arthritis (RA) and to compare the results with a normal control group. Materials and Methods: In this three-arm cross-sectional study, the sonographically measured median nerve cross-sectional area (MNCSA) was compared in three groups: RA patients with CTS, RA patients without CTS, and normal subjects (no RA, no CTS). A nerve conduction study (NCS) was performed for all enrolled participants, across the three study arms. Results: In this study, 38 RA patients (17 in CTS group and 21 in no CTS group) and 19 healthy subjects were recruited. The MNCSAs were 11.86 (±1.87) mm2 in RA patients with CTS, 10.16 (±1.71) mm2 in RA patients without CTS, and 9.42 (±1.46) mm² in healthy control patients. The accuracy of sonography in detecting CTS was 0.79 (95% confidence interval, 0.67–0.91), with a sensitivity and specificity of 88% and 57%, respectively. The MNCSA in CTS group was significantly higher than the control group ( P = .02). Conclusion: In this cohort, the sonographic measurement of MNCSA was an accurate and sensitive method for the diagnosis of CTS, especially in its early stages. In addition, in this cohort, RA without CTS did not increase the MNCSA.


  • Open Access

    Correlation between capillaroscopic findings and bone mineral density results in the systemic lupus erythematosus patients

    by Alireza Rajaei, Haleh Sadraee, Pooneh Dehghan, Mohammad Mehdi Emam, Arman Ahmadzadeh, Faraneh Farsad, Zahra Abbasi

    Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disorder that can cause vascular involvement. The vascular changes can be seen in the bed of the nails. It was observed that SLE has a relationship with bone mineral density (BMD) changes. Objectives: This study aimed to investigate the frequency and types of capillaroscopic change in SLE and its relationship between capillaroscopic changes with BMD in SLE. Patients and Methods: Thirty-three patients with SLE who were referred to Resalat hospital (Tehran, Iran) underwent nailfold capillaroscopy (NFC). In addition, these patients were evaluated for BMD from spine and hip. Moreover, the correlation of these data was assessed. Result: Scleroderma pattern was seen in 12.12% of patients, non-scleroderma pattern (NSP) in 27.3% patients and normal pattern in 60.6% based on NFC. There was no relationship between gender and NFC. The mean age was 43.30 years and 78.8% of patients were female. Dimension and morphological abnormalities had a relationship with scleroderma pattern (P=0.033 and P=0.014 respectively). There was a relationship between spine BMD and morphological abnormality too (P=0.013). Conclusion: NFC is a good method for evaluating vascular change in patients with SLE and in this method, abnormal morphology and dimension have higher prevalence than other abnormalities in patients with SLE. Additionally, a relationship between abnormal morphology in NFC and spinal osteoporosis in SLE patients was detected.

  • Evaluating Mannuronic Acid Effect on Gene Expression Profile of Inflammatory Mediators in Rheumatoid Arthritis Patients

    by Saiedeh Omidian, Zahra Aghazadeh, Arman Ahmadzadeh, Mona Aslani, Mostafa Hosseini, Simin Abbasi, Abbas Mirshafiey

    Rheumatoid arthritis (RA) is a multisystem disorder. Various studies have shown the important role of inflammatory factors tumor necrosis factor α (TNF-α), interleukin (IL)-6, IL-22, MYD88, and toll-like receptor 2 (TLR2) in this disease. In this study, we investigated the anti-inflammatory effects of B-D-Mannuronic acid (M2000), as a new immunosuppressive drug, on the expression of these inflammatory markers in peripheral blood mononuclear cells (PBMCs) of RA patients. The blood samples of 24 active RA patients and healthy volunteers were used for PBMCs separation. The cells were cultured with LPS (1 µg/mL), low (5 µg/mL), moderate (25 µg/mL), and high (50 µg/mL) doses of M2000 and a single dose of diclofenac (1 µg/mL) to evaluate TNF-α, IL-6, IL-22, MYD88, and TLR2 genes expression by quantitative real-time (qRT-PCR). Cell surface expression and MFI of TLR2 were assessed; using flow cytometry. Our findings exhibited a significant reduction of TNF-α, IL-6, and MYD88 gene expressions after treatment with three doses of M2000 and an optimum dose of diclofenac. TLR2 gene expression was significantly diminished by moderate and high doses of M2000 and a single dose of diclofenac. Moreoversurface expression of TLR2 was significantly downregulated by moderate and high doses of M2000, while MFI of this was significantly reduced by three doses of M2000. The results of this research showed that M2000 was able to significantly reduce the gene expression of inflammatory markers TNF-α, IL-6, MYD88, and TLR2 in patients PBMCs. These data revealed a part of the mechanisms of M2000 in the treatment process.


  • Study of the Effects of N-acetylcysteine on Inflammatory Biomarkers and Disease Activity Score in Patients with Rheumatoid Arthritis

    by Faezeh Jamali, Arman Ahmadzadeh, Zahra Sahraei, Jamshid Salamzadeh

    Rheumatoid arthritis (RA) is considered as an autoimmune-related condition in which the overproduction of pro-inflammatory cytokines leads to an inflammatory cascade. N-acetylcysteine (NAC) is a potent anti-inflammatory and anti-oxidant agent. We aimed to explore the impact of oral NAC on cytokines activities and clinical indicators in RA patients. In this placebo-controlled randomized double-blind clinical trial, 41 active RA patients were allocated in either NAC (600 mg, twice a day) or placebo group, as add-on therapy to the routine regimen, for 8 weeks. Disease activity score with an erythrocyte sedimentation rate (DAS28-ESR), and serum concentrations of interleukin (IL)-1β and IL-17 were assessed at baseline and end of the trial for all participants in the test and control groups. The reduction of the DAS28-ESR was higher considerably in the NAC group compared to that of the control group. No statistically significant differences were seen in the reduction of IL- 1β and IL-17 cytokines between the NAC and control groups. In addition, improvements in the patient global assessment, number of tender joints, number of swollen joints, and the ESR rates were in favor of the NAC group. Our findings reveal that NAC may have a beneficial effect on all of the clinical features of RA. However, non-significant variations in the IL-1β and IL-17 levels suggest an alternative way of NAC effectiveness without influencing the measured cytokines. Nevertheless, these results need to be confirmed by further investigations.


  • Open Access

    The prevalence of COVID-19 in patients with rheumatoid arthritis, multiple sclerosis, or systemic lupus erythematosus receiving biologic disease-modifying antirheumatic drugs

    by Arman Ahmadzadeh, Faraneh Farsad, Mohammad Mehdi Emam, Alireza Rajaei, Samaneh Hatami, Latif Gachkar

    Introduction: The coronavirus disease (COVID-19) became a global pandemic in 2019. Some studies have shown that the virus can cause a higher mortality in people with weakened immune systems, such as the elderly, those taking immunosuppressive drugs, and those with underlying disorders, than in the general population. Objectives: The aim of this study was to evaluate the prevalence of COVID-19 in patients with rheumatic disorders who received biologic disease-modifying antirheumatic drugs (DMARDs). The effect of precautionary self-isolation in these patients was also determined. Patients and Methods: This descriptive study involved 200 patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS) who were treated with biologic DMARDs. Patients with symptoms of the coronavirus infection were invited to have a COVID-19 test that involved a COVID-19 IgG antibody test or a polymerase chain reaction (PCR) test (i.e., nasal swab). Additionally, patients were asked about their precautionary self-isolation status during this period. Results: The mean age of the patients was 51.29 years ± 13.38 years. The ratio of males to females was 27 to 173. Of the 200 patients included in the study, 156 (78%) had RA, 10 (5%) had SLE, and 34 (17%) had MS. Seventy-five percent of the patients used rituximab. Ten patients (5%) were symptomatic of COVID-19, although only four patients had a definitive diagnosis of the disease. All patients who were symptomatic of COVID-19 took rituximab. Ten percent of patients who did not observe the precautionary self-isolation period were diagnosed with COVID-19. Conclusion: Patients who receive biologic DMARDs have a lower risk of developing COVID-19 and a lower risk of mortality from the disease than the general population.

  • Influence of β-D-mannuronic Acid, as a New Member of Non-steroidal Anti- Inflammatory Drugs Family, on the Expression Pattern of Chemokines and their Receptors in Rheumatoid Arthritis

    by Mona Aslani, Arman Ahmadzadeh, Zahra Aghazadeh, Majid Zaki-Dizaji, Laleh Sharifi, Mostafa Hosseini, Abbas Mirshafiey

    Background: Based on the encouraging results of phase III clinical trial of β-D-mannuronic acid (M2000) (as a new anti-inflammatory drug) in patients with RA, in this study, we aimed to evaluate the effects of this drug on the expression of chemokines and their receptors in PBMCs of RA patients. Methods: PBMCs of RA patients and healthy controls were separated and the patients' cells were treated with low, moderate and high doses (5, 25 and 50 μg/mL) of M2000 and optimum dose (1 μg/mL) of diclofenac, as a control in RPMI-1640 medium. Real-time PCR was used for evaluating the mRNA expression of CXCR3, CXCR4, CCR2, CCR5 and CCL2/MCP-1. Cell surface expression of CCR2 was investigated using flow cytometry. Results: CCR5 mRNA expression reduced significantly, after treatment of the patients' cells with all three doses of M2000 and optimum dose of diclofenac. CXCR3 mRNA expression down-regulated significantly followed by treatment of these cells with moderate and high doses of M2000 and optimum dose of diclofenac. CXCR4 mRNA expression declined significantly after treatment of these cells with moderate and high doses of M2000. CCL2 mRNA expression significantly reduced only followed by treatment of these cells with high dose of M2000, whereas, mRNA and cell surface expressions of CCR2 diminished significantly followed by treatment of these cells with high dose of M2000 and optimum dose of diclofenac. Conclusion: According to our results, M2000 through the down-regulation of chemokines and their receptors may restrict the infiltration of immune cells into the synovium.


  • Open Access

    miRNAs and rheumatoid arthritis: new update in expression pattern and pathogenicity

    by Hamidreza Ebrahimiyan, Arman Ahmadzadeh

    Rheumatoid arthritis (RA) is a polygenic autoimmune disease characterized by systemic inflammation and disability of joints. Early diagnosis and treatment could prevent diseases in RA patients from becoming severe. miRNAs are small, non-coding RNA that regulate the post-transcriptional level of gene expression. miRNAs play important roles in gene expression and pathogenicity of autoimmune diseasesas well as RA. Properly using miRNAs regulation potential and detecting different expression patterns andtheir functions could facilitate and manage effective therapeuticinterventions in RA patients. Herein, we discuss miRNAs as a therapeutic agent in RA patients.